Jeff Yass’s Endocyte, Inc. Common Stock ECYT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2018
Q4 | – | Sell |
-93,000
| Closed | -$1.65M | – | 10562 |
|
|
2018
Q3 | $1.65M | Sell |
93,000
-174,500
| -65% | -$3M | ﹤0.01% | 4308 |
|
|
2018
Q2 | $3.69M | Buy |
267,500
+185,400
| +226% | +$2.2M | ﹤0.01% | 3105 |
|
|
2018
Q1 | $746K | Sell |
82,100
-99,000
| -55% | -$546K | ﹤0.01% | 5830 |
|
|
2017
Q4 | $775K | Buy |
181,100
+52,000
| +40% | +$248K | ﹤0.01% | 5750 |
|
|
2017
Q3 | $182K | Sell |
129,100
-3,200
| -2% | -$4.46K | ﹤0.01% | 8085 |
|
|
2017
Q2 | $198K | Buy |
132,300
+118,500
| +859% | +$254K | ﹤0.01% | 8303 |
|
|
2017
Q1 | $35K | Sell |
13,800
-3,700
| -21% | -$8.56K | ﹤0.01% | 8653 |
|
|
2016
Q4 | $45K | Buy |
17,500
+2,300
| +15% | +$6.6K | ﹤0.01% | 9313 |
|
|
2016
Q3 | $47K | Buy |
+15,200
| New | +$47.4K | ﹤0.01% | 8141 |
|
|
2016
Q2 | – | Sell |
-30,800
| Closed | -$95K | – | 9749 |
|
|
2016
Q1 | $95K | Sell |
30,800
-25,000
| -45% | -$81.6K | ﹤0.01% | 8458 |
|
|
2015
Q4 | $224K | Sell |
55,800
-57,000
| -51% | -$262K | ﹤0.01% | 8238 |
|
|
2015
Q3 | $517K | Sell |
112,800
-95,400
| -46% | -$499K | ﹤0.01% | 7055 |
|
|
2015
Q2 | $1.08M | Sell |
208,200
-64,200
| -24% | -$385K | ﹤0.01% | 6059 |
|
|
2015
Q1 | $1.71M | Sell |
272,400
-3,900
| -1% | -$22.5K | ﹤0.01% | 4627 |
|
|
2014
Q4 | $1.74M | Sell |
276,300
-363,800
| -57% | -$2.22M | ﹤0.01% | 4731 |
|
|
2014
Q3 | $3.89M | Sell |
640,100
-1,100
| -0.2% | -$7.51K | ﹤0.01% | 3416 |
|
|
2014
Q2 | $4.23M | Buy |
641,200
+391,300
| +157% | +$4.41M | ﹤0.01% | 3351 |
|
|
2014
Q1 | $5.95M | Buy |
249,900
+217,800
| +679% | +$3.16M | ﹤0.01% | 2652 |
|
|
2013
Q4 | $343K | Sell |
32,100
-16,600
| -34% | -$183K | ﹤0.01% | 7369 |
|
|
2013
Q3 | $649K | Buy |
48,700
+4,300
| +10% | +$68K | ﹤0.01% | 6023 |
|
|
2013
Q2 | $583K | Buy |
+44,400
| New | +$599K | ﹤0.01% | 5828 |
|
Other funds holding ECYT
Jeff Yass's ECYT Position: Q2 2018 in Review
Jeff Yass sold out of Endocyte, Inc. Common Stock (ECYT) in Q2 2018, closing a stake of 499,801 shares — an estimated $5.93M sold.
Jeff Yass first reported a position in ECYT in Q2 2013 and held it in 19 quarters. The position peaked at $4.54M in Q1 2018. 114 funds tracked by Wall St. Rank hold ECYT as of Q2 2018.
- Jeff Yass reported no remaining Endocyte, Inc. Common Stock position as of Q2 2018 after selling out during the quarter.
- Jeff Yass sold 499,801 Endocyte, Inc. Common Stock shares in Q2 2018, an estimated $5.93M.
- Jeff Yass first reported a position in Endocyte, Inc. Common Stock in Q2 2013 and held it in 19 quarters.
- Jeff Yass's Endocyte, Inc. Common Stock position peaked at $4.54M in Q1 2018.
- 114 funds tracked by Wall St. Rank held Endocyte, Inc. Common Stock as of Q2 2018.
Based on Susquehanna International Group's 13F filing for Q2 2018, filed 14 Aug 2018.